Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Maxigen Biotech's Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$304.9 Mil. Therefore, Maxigen Biotech's EV-to-EBIT ratio for today is 8.94.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Maxigen Biotech's Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$337.1 Mil. Therefore, Maxigen Biotech's EV-to-EBITDA ratio for today is 8.09.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Maxigen Biotech's Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$811.6 Mil. Therefore, Maxigen Biotech's EV-to-Revenue ratio for today is 3.36.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Maxigen Biotech's Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$207.6 Mil. Therefore, Maxigen Biotech's EV-to-FCF ratio for today is 13.13.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Maxigen Biotech (TPE:1783) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Maxigen Biotech's current Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$304.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Maxigen Biotech's current Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$337.1 Mil.
Maxigen Biotech's current Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$811.6 Mil.
Maxigen Biotech's current Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$290.2 Mil.
Maxigen Biotech's current Enterprise Value is NT$2,725.7 Mil.
Maxigen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$207.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech Enterprise Value Related Terms
Maxigen Biotech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Maxigen Biotech's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$2,725.7 Mil mean?
Maxigen Biotech (TPE:1783) has a Enterprise Value of NT$2,725.7 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Maxigen Biotech and its competitors.
Is Maxigen Biotech's Enterprise Value too high?
Maxigen Biotech's current Enterprise Value is NT$2,725.7 Mil. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Enterprise Value compare to ISRG and BDX?
Maxigen Biotech's Enterprise Value of NT$2,725.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current Enterprise Value is NT$2,725.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.08, compared to a current price of NT$39.05 — trading 36.1% below its estimated fair value. The current Enterprise Value is NT$2,725.7 Mil. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Enterprise Value is NT$2,725.7 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$39.05 is trading 36.1% below its estimated GF Value™ of NT$61.08.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Enterprise Value: NT$2,725.7 Mil
GF Value™: NT$61.08 vs. price of NT$39.05 (36.1% below fair value)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
